August 2012 has been a busy month for late-stage testing of long awaited Alzheimer’s drugs. Unfortunately, the results haven’t been good. In early August, information was released disclosing that Pfizer’s bapineuzumab did not meet the primary endpoints set up by the studies, and trials were stopped. Now, Eli Lilly has also announced that their contribution to the Alzheimer’s battle, solanezumab, did not meet the primary endpoints, both cognitive and functional, in either of the two Phase 3, double-blind, placebo-controlled studies on the drug.

Read more about the last drug on the list that didn't pass:

Purchase Minding Our Elders: Caregivers Share Their Personal Stories – paperback or ebook